MarketWatch (press release) The most frequent adverse reactions seen in patients with EGFR-expressing metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater-than or equal to50%) were acneiform rash (88%), asthenia/malaise ... and more »
MarketWatch (press release) The most frequent adverse reactions seen in patients with EGFR-expressing metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater-than or equal to50%) were acneiform rash (88%), asthenia/malaise ... and more »
MarketWatch (press release) The most frequent adverse reactions seen in patients with EGFR-expressing metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater-than or equal to50%) were acneiform rash (88%), asthenia/malaise ... and more »
The Herald | HeraldOnline.com The company pipeline includes two clinical stage products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan :floxuridine) for the treatment of ... and more »
pharmabiz.com Vectibix was approved in the United States in September 2006 as a single agent for the treatment of patients with EGFR-expressing mCRC with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan -containing chemotherapy ...
MarketWatch (press release) ... AZD6244, ARRY-142886) plus irinotecan as second-line therapy for KRAS-mutated metastatic colorectal cancer (Abstract #3587) Presenter: Howard S. Hochster, MD Date: Sunday, June 2, 8 - 11:45 a.m. CDT Title: Dual MEK/EGFR inhibition for advanced, ...
MarketWatch (press release) The most frequent adverse reactions seen in patients with EGFR-expressing metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater-than or equal to50%) were acneiform rash (88%), asthenia/malaise ... and more »
